Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 11, 2013, Pages 1066-1070

  Nobili, V ^a   Alisi, A ^a   Della Corte, C ^a   Rise P ^b   Galli, C ^b   Agostoni, C ^b   Bedogni, G ^a,b,c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Liver Research Center   (Italy)

Author keywords

Adolescents; Children; Docosahexaenoic acid; Long chain polyunsaturated fatty acids; Non alcoholic fatty liver disease; Randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; DOCOSAHEXAENOIC ACID; PLACEBO; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; DIET SUPPLEMENTATION; ECHOGRAPHY; FEMALE; FOLLOW UP; GAS CHROMATOGRAPHY; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENTS; CHILDREN; DOCOSAHEXAENOIC ACID; LONG-CHAIN POLYUNSATURATED FATTY ACIDS; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; BODY MASS INDEX; CHILD; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOWN-REGULATION; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPATIC INSUFFICIENCY; HOSPITALS, PEDIATRIC; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ITALY; LIPID METABOLISM; LIVER; MALE; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 84887609640     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.10.010     Document Type: Article

References (23)

1. Alisi A., Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition 2012, 28:722-726.
2. Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 57:157-166.
3. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53:372-384.
4. Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009, 48:587-596.
5. Masterton G.S., Plevris J.N., Hayes P.C. Review article: omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010, 31:679-692.
6. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012, 56:944-951.
7. Nobili V., Bedogni G., Alisi A., Pietrobattista A., Risé P., Galli C., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011, 96:350-353.
8. Nobili V., Marcellini M., Devito R., Ciampalini P., Piemonte F., Comparcola D., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44:458-465.
9. EFSA Panel on Dietetic Products Nutrition and allergies (NDA). Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J 2012, 10:2815-2848.
10. Bedogni G., Gastaldelli A., Manco M., De Col A., Agosti F., Tiribelli C., et al. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutr Metab Cardiovasc Dis 2012, 22:120-126.
11. Shannon A., Alkhouri N., Carter-Kent C., Monti L., Devito R., Lopez R., et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr 2011, 53:190-195.
12. Lohman T.G., Roche A.F., Martorell R. Anthropometric standardization reference manual 1988, Human Kinetics Books, Champaign, IL.
13. Kuczmarski R.J., Ogden C.L., Grummer-Strawn L.M., Flegal K.M., Guo S.S., Wei R., et al. CDC growth charts: United States. Adv Data 2000, 1-27.
14. Marangoni F., Colombo C., Galli C. A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: applicability to nutritional and epidemiological studies. Anal Biochem 2004, 326:267-272.
15. Rabe-Hesketh S., Skrondal A. Multilevel and longitudinal modeling using Stata. continuous responses 2012, vol. 1. Stata Press, College Station, TX.
16. Rabe-Hesketh S., Skrondal A. Multilevel and longitudinal modeling using Stata. categorical responses, counts and survival 2012, vol. 2. Stata Press, College Station, TX.
17. Williams R. Fitting heterogeneous choice models with OGLM. Stata J 2010, 10:540-567.
18. Agresti A. Analysis of ordinal categorical data 2010, Wiley, Hoboken, N.J.
19. Bedogni G., Kahn H.S., Bellentani S., Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010, 10:98.
20. Williams R. Generalized ordered logit/partial proportional odds models for ordinal dependent variables. Stata J 2006, 6:58-82.
21. Thorsdottir I., Tomasson H., Gunnarsdottir I., Gisladottir E., Kiely M., Parra M.D., et al. Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int J Obes Relat Metab Disord 2007, 31:1560-1566.
22. DeFina L.F., Marcoux L.G., Devers S.M., Cleaver J.P., Willis B.L. Effects of omega-3 supplementation in combination with diet and exercise on weight loss and body composition. Am J Clin Nutr 2011, 93:455-462.
23. Bedogni G., Miglioli L., Masutti F., Castiglione A., Crocè L.S., Tiribelli C., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007, 46:1387-1391.